Back to Browse Journals » Clinical Interventions in Aging » Volume 3 » Issue 2

Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problems

Authors Randi J Hagerman, Deborah A Hall, Sarah Coffey, Maureen Leehey, James Bourgeois, et al

Published Date June 2008 Volume 2008:3(2) Pages 251—262

DOI http://dx.doi.org/10.2147/CIA.S1794

Published 30 June 2008

Randi J Hagerman1,2, Deborah A Hall3, Sarah Coffey1,2, Maureen Leehey3, James Bourgeois4, John Gould5, Lin Zhang6, Andreea Seritan4, Elizabeth Berry-Kravis7–9, John Olichney6, Joshua W Miller10, Amy L Fong11, Randall Carpenter12, Cathy Bodine13, Louise W Gane1,2, Edgar Rainin1, Hillary Hagerman1, Paul J Hagerman14

1M.I.N.D. Institute, 2Department of Pediatrics, 4Department of Psychiatry & Behavioral Sciences, 5Department of Urology, 6Department of Neurology, 10Department of Pathology and Laboratory Medicine, 14Department of Biochemistry and Molecular Medicine, University of California, Davis, School of Medicine, Sacramento, CA, USA; 3Department of Neurology, University of Colorado, Denver, CO, USA; 7Department of Pediatrics, Neurology, and Biochemistry, 8Department of Neurological Sciences, 9Department of Biochemistry, Rush University Medical Center, Chicago, IL, USA; 11Physical Edge, Inc., Davis, CA, USA; 12Seaside Therapeutics, Cambridge, MA, USA; 13Department of Physical Medicine and Rehabilitation, University of Colorado Health Sciences Center, Denver, CO, USA

Abstract: Fragile X-associated tremor/ataxia syndrome (FXTAS) is a progressive neurological disorder that affects older adult carriers, predominantly males, of premutation alleles (55 to 200 CGG repeats) of the fragile X (FMR1) gene. Principal features of FXTAS are intention tremor, ataxia, parkinsonism, cognitive decline, and peripheral neuropathy; ancillary features include, autonomic dysfunction, and psychiatric symptoms of anxiety, depression, and disinhibition. Although controlled trials have not been carried out in individuals with FXTAS, there is a significant amount of anecdotal information regarding various treatment modalities. Moreover, there exists a great deal of evidence regarding the efficacy of various medications for treatment of other disorders (eg, Alzheimer disease) that have substantial phenotypic overlap with FXTAS. The current review summarizes what is currently known regarding the symptomatic treatment, or potential for treatment, of FXTAS.

Keywords: fragile X syndrome, dementia, ataxia, neurodegeneration, parkinsonism, tremor

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Modulation of the GABAergic pathway for the treatment of fragile X syndrome

Lozano R, Hare EB, Hagerman RJ

Neuropsychiatric Disease and Treatment 2014, 10:1769-1779

Published Date: 16 September 2014

Readers of this article also read:

Self-assembled polymeric nanoparticles as new, smart contrast agents for cancer early detection using magnetic resonance imaging

Mouffouk F, Simão T, Dornelles DF, Lopes AD, Sau P, Martins J, Abu-Salah KM, Alrokayan SA, Rosa da Costa AM, dos Santos NR

International Journal of Nanomedicine 2015, 10:63-76

Published Date: 17 December 2014

Response to vitamin D and depression in geriatric primary care patients

Muc-Wierzgoń M, Nowakowska-Zajdel E, Klakla K, Dzięgielewska-Gęsiak S, Fatyga E, Kokot T

Clinical Interventions in Aging 2013, 8:825-827

Published Date: 3 July 2013

BAK additive influence on results

Shah RD, Lemon TI, Yarrow-Jenkins A

Clinical Ophthalmology 2013, 7:1081-1082

Published Date: 6 June 2013

Targeting nanomaterials: future drugs for cancer chemotherapy

Zhang Y, Chen T

International Journal of Nanomedicine 2012, 7:5283-5286

Published Date: 10 October 2012

Corrigendum

Hong SH, Kim JE, Kim YK, Minai-Tehrani A, Shin JY, Kang B, Kim HJ, Cho CS, Chae C, Jiang HL, Cho MH

International Journal of Nanomedicine 2012, 7:3069-3070

Published Date: 20 June 2012

Corrigendum

Schneider EW, Johnson MW

Clinical Ophthalmology 2011, 5:1315-1316

Published Date: 16 September 2011

Corrigendum: Softec HD hydrophilic acrylic intraocular lens: biocompatibility and precision

Espandar L, Sikder S, Moshirfar M

Clinical Ophthalmology 2011, 5:159-160

Published Date: 6 February 2011

Propaedeutic study for the delivery of nucleic acid-based molecules from PLGA microparticles and stearic acid nanoparticles

G Grassi, N Coceani, R Farra, B Dapas, G Racchi, et al

International Journal of Nanomedicine 2006, 1:523-533

Published Date: 8 May 2006